Peptide News Digest

Crinetics Palsonify 2-Year OLE at ENDO 2026, GLP-1 Patients Walk 560 Fewer Steps, Semaglutide Cuts Fractures 15%, Ascendis TransCon CNP 2-Year ApproaCH, GLP-1s and Male Fertility

ENDO 2026 day 2: Crinetics Palsonify 2-yr OLE confirms acromegaly control; GLP-1 secondary effects on activity, fractures, fertility; TransCon CNP year 2.

5 stories · Covering clinical-trials, research

Editor's Note

ENDO 2026 Day 2 in Chicago delivered the cleanest non-GLP-1 peptide data of the meeting. Crinetics reported up to two years of efficacy and safety from the PATHFNDR-1 and PATHFNDR-2 open-label extensions of Palsonify (paltusotine), the once-daily oral SST2 nonpeptide agonist for acromegaly: lower IGF-1 maintained, stable symptoms, and stable or reduced pituitary tumor volumes through 48 weeks across 167 patients. With Camurus's Oclaiz pushed to a 2027 US launch after this week's second manufacturing CRL, Palsonify now sits alone as the next-generation acromegaly therapy on the US market. Saturday produced a second narrative thread: three GLP-1 secondary-effects studies from the press conference cycle (a 560-step daily activity drop on GLP-1s from Stanford and NIH All of Us, a 15% lower fracture risk on semaglutide in T2D from Atropos Health, and a male-fertility benefit in obesity-related low testosterone from a UK meta-analysis). Ascendis added 2-year ApproaCH trial data for TransCon CNP (YUVIWEL, navepegritide), the once-weekly C-natriuretic peptide prodrug for achondroplasia approved by the FDA in February 2026, showing sustained annualized growth velocity through year two in children 5 and older.

Clinical Trials

Crinetics Presents 2-Year Palsonify (Paltusotine) Open-Label Extension Data at ENDO 2026, Confirms Durable Acromegaly Control

Crinetics Pharmaceuticals (Nasdaq: CRNX) presented data on June 14 from up to two years of efficacy and pooled safety follow-up in the PATHFNDR-1 and PATHFNDR-2 open-label extensions of Palsonify, the once-daily oral SST2 nonpeptide agonist for acromegaly. Palsonify maintained lowered IGF-1 levels, stable symptoms, and stable or reduced pituitary tumor volumes through 48 weeks across 167 patients. Pooled safety data identified no new safety signals; common adverse events were diarrhea, arthralgia, headache, and UTI. A separate ACROBAT Advance analysis showed safety and efficacy with up to four years of Palsonify + oral cabergoline combination therapy in patients whose IGF-1 had not normalized on Palsonify alone. With Camurus's rival monthly octreotide depot Oclaiz pushed to a 2027 US launch after the June 10 second CRL, Palsonify now stands alone as the next-generation acromegaly therapy in the US market.

#crinetics #palsonify #paltusotine #acromegaly #pathfndr-1 #pathfndr-2 #endo-2026 #open-label-extension
Research

ENDO 2026 Study: GLP-1 Users Walk 560 Fewer Steps Per Day, Lose 5.7 Minutes of Moderate-to-Vigorous Activity

A Stanford-led retrospective pre-post cohort study presented June 13 at ENDO 2026 in Chicago used NIH All of Us Research Program data linking electronic health records with Fitbit activity in 1,950 adults with obesity who started GLP-1 medications. Among the 753 with sufficient wearable data, mean daily steps dropped from 5,047 before GLP-1 initiation to 4,487 after (-560 steps, p<0.001); moderate-to-vigorous activity fell from 27.9 to 22.2 minutes per day (-5.7 minutes, p<0.001). The largest declines occurred in men and in people with pre-existing joint or muscle pain; age, heart failure, and stroke history did not change the pattern. Lead author Surya Maharjan flagged the activity drop as a concern given GLP-1-associated lean-mass loss.

#glp-1 #physical-activity #fitbit #all-of-us #lean-mass #endo-2026 #real-world-evidence
Research

ENDO 2026 Study: Semaglutide Linked to 15% Lower Fracture Risk Compared to Other Anti-Obesity Medications in T2D

Stanford University researchers presented retrospective cohort data at ENDO 2026 on June 13 from the Atropos Health Eos electronic health record dataset (~161 million patients seen in US community hospitals and academic medical centers, January 2016 to December 2023). Among adults with type 2 diabetes and no prior fractures or osteoporosis medication use, semaglutide was associated with a 15% lower fracture risk and greater weight loss versus other anti-obesity medications. Principal investigator Jairo Noreña framed the work as an early signal that semaglutide-driven weight loss may protect bone health in T2D, with prospective studies needed to confirm.

#semaglutide #fracture-risk #bone-health #type-2-diabetes #real-world-evidence #endo-2026 #atropos-health
Clinical Trials

Ascendis TransCon CNP (YUVIWEL, Navepegritide) 2-Year ApproaCH Data: Sustained Growth Velocity in Children 5+ With Achondroplasia at ENDO 2026

Ascendis Pharma (Nasdaq: ASND) presented a subgroup analysis from the registrational ApproaCH trial of once-weekly TransCon CNP (navepegritide, brand name YUVIWEL) at ENDO 2026 in Chicago showing sustained annualized growth velocity (AGV) gains through two years of treatment in children 5 years and older with achondroplasia. Investigators reported significantly greater AGV at week 52 versus placebo with improvements sustained through year two. TransCon CNP was FDA-approved in February 2026 under the YUVIWEL brand to increase linear growth in pediatric patients 2 years of age and older with achondroplasia and open epiphyses. The C-natriuretic peptide prodrug is the second TransCon-platform asset approved after TransCon hGH (Skytrofa) for pediatric growth hormone deficiency.

#ascendis-pharma #transcon-cnp #navepegritide #yuviwel #achondroplasia #approach-trial #c-natriuretic-peptide #endo-2026
Research

ENDO 2026 Study: GLP-1s May Improve Testosterone and Sperm Quality in Men With Obesity-Related Low Testosterone

A research team from University Hospitals Coventry and Warwickshire and Warwick Medical School presented meta-analysis data from randomized controlled trials at ENDO 2026 on June 14 showing that 24 weeks of GLP-1 receptor agonist treatment improved testosterone levels, sperm count, and sperm morphology in men ages 18 to 65 with obesity-related low testosterone. Principal investigator Pratibha Natesh proposed reduced inflammation and metabolic stress as candidate mechanisms, with the GLP-1 class potentially preferable to testosterone replacement therapy in this population because TRT can suppress endogenous sperm production. The findings were drawn from men with high BMI, so external validity to normal-weight populations is unclear.

#glp-1 #male-fertility #testosterone #sperm-quality #obesity #hypogonadism #endo-2026